Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

NCT06250504 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

2000

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: APRETUDE (cabotegravir) 600 mg\3 mL
DRUG: DAPIRING (Dapivirine) 25mg Vaginal Ring
DRUG: tenofovir disoproxil and emtricitabine
DRUG: Tenofovir Disoproxil, Lamuvidine and Dolutegravir

Sponsor

Africa Health Research Institute